Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2006, p. 1463-1479, Vol. 26, No. 4
0270-7306/06/$08.00+0 doi:10.1128/MCB.26.4.1463-1479.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Akihide Ryo,
Gerburg Wulf,
Jormay Lim, and
Kun Ping Lu*
Cancer Biology Program, Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215
Received 9 August 2005/ Returned for modification 23 September 2005/ Accepted 22 November 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Accurate chromosome segregation to each daughter cell during mitosis requires the duplication of centrosomes once and only once during each cell cycle (7, 18, 33, 56, 70). Centrosome duplication initiates at the G1/S transition and is completed during S phase in mammalian somatic cells. Centrosome duplication must be coupled to the events of the nuclear cell cycle, and their decoupling can result in abnormal centrosome numbers and aberrant mitosis, leading to chromosome instability. This strict coordination has been shown to be regulated by multiple pathways. One major pathway is the activation of Cdk2/cyclin E or A during the G1/S transition (32, 36, 49, 52). Furthermore, E2F activation and Rb phosphorylation by Cdk2 are also required for centrosome duplication (52). Moreover, Cdk2 might be subjected to the regulation of p53-mediated cell cycle checkpoints (13, 22, 28). Finally, several centrosome Cdk substrates have been identified, including BRCA1, nucleophosmin/B23, mMPS1/ESK, and CP110, that play an important role in centrosome duplication (10, 23, 57, 83). These results indicate that Cdk2-mediated protein phosphorylation plays a key role in regulating centrosome duplication during the S phase. However, little is known about whether the coordination between DNA synthesis and centrosome duplication is further regulated after phosphorylation.
Cyclin-dependent protein kinases are Pro-directed kinases that regulate cell cycle progression by phosphorylating exclusively on serine or threonine residues preceding a proline (Ser/Thr-Pro). Although these phosphorylation events have been proposed to function via inducing conformational changes, little was known about the nature and regulation of the conformational changes until recently (45). Recent studies indicate that certain phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs in proteins can exist in the two completely distinct cis and trans conformations; their conversion is normally inhibited by phosphorylation but is specifically catalyzed by the prolyl isomerase Pin1 (44, 45, 63, 84). Pin1 contains an N-terminal WW domain and a C-terminal prolyl isomerase domain. The WW domain binds to specific pSer/Thr-Pro motifs and targets Pin1 to a subset of phosphoproteins, while the isomerase domain induces conformational changes by catalyzing the isomerization of specific pSer/Thr-Pro bonds (47, 84, 90). Such conformational changes have been shown to have profound effects on the function of Pin1 substrates by modulating their catalytic activity, phosphorylation status, protein-protein interaction, subcellular localization, and stability (41, 42, 67, 68, 74, 79, 81, 82, 84, 87, 88, 90). Consequently, Pin1 has been shown to be involved in the regulation of many cellular processes, such as cell proliferation and differentiation (2, 16, 41, 42, 44, 45, 48, 78, 79, 85).
An increasing body of evidence suggests that Pin1 may play an important role in oncogenesis and may be a potential new anticancer target. Pin1 is overexpressed in a large number of human cancers and is also an excellent prognostic marker of poor outcome in some cancers (5, 43, 65, 67, 82). Furthermore, Pin1 can function as a critical catalyst that amplifies multiple oncogenic signaling pathways such as the Neu/Ras/c-Jun, Wnt/ß-catenin, and cytokine/NF-
B pathways (67, 68, 82) and its overexpression can transform immortal breast epithelial cells in vitro (66). In contrast, the inhibition of Pin1 in cancer cells via multiple approaches either triggers apoptosis or suppresses transformed phenotypes (44, 46, 64) and Pin1 knockout suppresses the ability of certain oncogenes to induce breast cancer (80). These findings indicate that Pin1 is prevalently overexpressed in human cancers and is important for the activation of multiple oncogenic pathways. However, little is known about the significance of Pin1 overexpression in cancer development in vivo. Furthermore, although cyclin D1, a key molecule in oncogenesis (15, 37, 72, 77, 86) and a major Pin1 downstream target in oncogenesis (41, 67, 68, 80, 82), has been implicated in centrosome amplification in vitro (55), nothing is known about the role of Pin1 in centrosome duplication and chromosome stability.
In this study, we have shown that Pin1 localizes to and copurifies with centrosomes and regulates centrosome duplication. Furthermore, the ablation of Pin1 in mouse embryonic fibroblasts specifically delays centrosome duplication during S phase, whereas overexpression of Pin1 in nontransformed cells induces centrosome amplification, abnormal mitotic spindle formation, chromosome missegregation eventually leading to aneuploidy, and oncogenic transformation. Moreover, the overexpression of Pin1 in transgenic mouse mammary glands also potently causes centrosome amplification, eventually leading to mammary hyperplasia and malignant mammary tumors with overamplified centrosomes. Together with the findings that Pin1 levels strongly correlate with centrosome amplification in human breast cancer tissues, these results indicate that Pin1 is an important regulator of centrosome duplication and that its overexpression can contribute to centrosome abnormality, chromosome instability, and oncogenesis.
| MATERIALS AND METHODS |
|---|
|
|
|---|
-tubulin (Sigma) or antipericentrin as described previously (67) and immunoblotting was also performed as described previously (67). Isolation of centrosome fraction. Isolation of centrosomes was carried out according to a published procedure (8), with the following minor modifications. Cultured cells were incubated with 10 µg/ml nocodazole and 5 µg/ml cytochalasin B for 2 h, rinsed with an isolation buffer (1 mM Tris, pH 8, 0.5 mM EGTA, 0.1% ß-mercaptoethanol), and then lysed by swaying the dishes in the isolation buffer containing 0.5% NP-40 at 4°C for 10 min. Next, a 1/50 vol of buffer {0.5 M PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid)], pH 7.2, 0.1 M EGTA} was added to the extracts, followed by loading onto discontinuous sucrose density gradient set with 3.5 ml of 60% sucrose and 3.5 ml of 40% sucrose prepared in 20 mM PIPES, pH 6.8, 0.5 mM MgCl2, 1 mM EGTA, and 0.1% ß-mercaptoethanol and centrifugation for 1 h at 14,500 rpm. Fractions were collected from the bottom and subjected to immunoblotting as described previously (67).
Analysis of centrosome duplication during S phase.
Centrosome duplication assays in Chinese hamster ovary (CHO) cells were performed as described previously (4, 52). Briefly, cells were transfected with the indicated DNA constructs by electroporation (Bio-Rad) according to the manufacturer's instructions. Twelve hours after transfection, hydroxyurea was added at a final concentration of 4 mM for 40 h. Cells were then fixed with formaldehyde for 15 min at room temperature and then with cold methanol for 10 min. Cells were then stained for centrosomes with anti-
-tubulin or antipericentrin antibodies and analyzed by fluorescent microscopy as described previously (67). DNA synthesis was monitored using the BrdU labeling kit (Roche) according to the manufacturer's instructions with Alexa594-conjugated goat anti-rabbit immunoglobulin G secondary antibodies (Molecular Probes).
To reexpress Pin1 in Pin1/ mouse embryonic fibroblasts (MEFs), MEFs derived from Pin1/ mouse embryos and immortalized using the 3T3 protocol as used previously (41, 68) were infected with the pBabe retroviruses expressing Pin1 or control retroviruses; this was followed by selection with puromycin to generate stable rescued Pin1/ and control Pin1/ MEFs. To analyze centrosome duplication during the cell cycle, Pin1/ and rescued Pin1/ MEFs were incubated with 70 ng/ml nocodazole for 16 h to synchronize cells at late G2 and M phases and then released from the arrest, followed by collecting samples for every 2 h for flow cytometry to analyze cell cycle progression and by immunostaining with anti-
-tubulin to determine centrosome duplication.
Electron microscopy. For electron microscopy, cells were fixed for 30 min at room temperature in a buffer containing 0.15 M sodium cacodylate (pH 7.0) and 0.2% glutaraldehyde and processed for electron microscopy as described previously (23, 50)
Analysis of ploidy and cell transformation assays. Asynchronously growing cells were treated with Colcemid (10 mg/ml; Roche) for 1 h and harvested by trypsinization, followed by resuspension in 10 ml of hypotonic buffer (0.2% KCl/0.2% trisodium citrate) for 12 min at 37°C. After adding 1 ml of an ice-cold fixative (3:1, methanol:acetic acid) for 5 min on ice, cells were harvested and resuspended twice more in 10 ml of the fixative. Finally, cells were dropped onto glass coverslips and at least 100 chromosome spreads per group were analyzed. Cell transformation assays were performed as described previously (66).
Generation of Pin1 transgenic mice. The human Pin1 cDNA with an NH2-terminal hemagglutinin (HA) epitope tag was subcloned under the control of the mouse mammary tumor virus (MMTV) promoter (provided by P. Leder), followed by microinjection into FVB fertilized eggs to generate transgenic mice as described previously (73). Multiple independent founder mouse lines were obtained and confirmed by Southern and Western blotting to express Pin1 and displayed the similar phenotypes observed.
Primary cultures of mammary epithelial cells and mammary tumor cells and mammary gland whole mounts. Primary cultures of mammary epithelial cells (MECs) and mammary tumor cells derived from mice were performed as described previously (80), as were mammary gland whole mounts (41, 80). Briefly, mammary glands or tumors were mechanically disaggregated and then subjected to sequential digestions with collagenase and trypsin. Isolated cells were resuspended in mammary epithelial growth medium and plated on collagen-coated culture dishes; this was followed by analyzing centrosome number within a few days to 1 week. To examine the development of the mammary epithelium, the no. 4 mammary glands of nonpregnant MMTV-Pin1 or control mice were dissected, spread onto a glass slide, and fixed, followed by fat removal with acetone. The glands were stained overnight in 0.2% carmine red (Sigma) and 0.5% AlK(SO4)2, dehydrated in graded ethanol solutions, followed by clearing in toluene and methyl salicylate. Photos were taken using a dissecting microscope.
Statistical analysis. MMTV-Pin1 transgenic and control cohorts were considered for the analysis of the end point, breast cancer-free survival using the Kaplan-Meier method; this was followed by determining the significance of the differences in disease-free survival among the cohorts using a log-rank (Mantel-Cox) test as described previously (80).
| RESULTS |
|---|
|
|
|---|
|
-tubulin, a centrosome marker. Consistent with previous studies (44, 46), GFP-Pin1 was found to localize primarily in the nucleus of cultured cells but, interestingly, the colocalization of Pin1 and
-tubulin was also observed as dots adjacent to the nucleus, a characteristic of centrosome staining (Fig. 2A). Importantly, the colocalization of Pin1 and
-tubulin at the centrosome was not detected in cells in mitotic phase (Fig. 2A), indicating a cell cycle-specific colocalization of exogenously expressed Pin1 with centrosomes.
|
-tubulin antibodies. Endogenous Pin1 was specifically detected in fractions that contained centrosomes, as determined by cosedimentation with
-tubulin at the expected sucrose densities (Fig. 2C). Similar colocalization and copurification between Pin1 and centrosomes were also observed in HeLa and CHO cells (data not shown). Taken together, these data indicate that both endogenous and exogenously expressed Pin1 proteins localize to centrosomes during only interphase, not mitotic phase, even although proteins at centrosomes are well known to be phosphorylated during mitosis (18, 53, 56, 70).
Inhibition of Pin1 suppresses centrosome amplification in S-arrested CHO cells.
Given that Pin1 localizes to centrosomes in interphase when centrosomes are duplicated, we next examined whether the inhibition of Pin1 function might affect centrosome duplication. For this purpose, we first used CHO cells, a cell model system widely used to study centrosome duplication because their centrosomes undergo multiple rounds of duplication when cells are arrested in S phase with hydroxyurea (4, 35, 49, 52). To inhibit cellular Pin1 function in hamster cells, we used a GFP-Pin1 WW domain mutant which contains an Ala substitution at Ser16, as this mutant has been previously shown to constitutively bind to endogenous Pin1 substrates but fails to catalyze the isomerization, thereby inhibiting endogenous Pin1 function in a dominant-negative manner (dn-Pin1) (46, 66). CHO cells were transfected with plasmid encoding either GFP control vector, GFP-Pin1, or GFP-dn-Pin1 and then treated with hydroxyurea for 40 h; this was followed by evaluating the number of centrosomes after staining with anti-
-tubulin. As expected, GFP-Pin1 and GFP-dn-Pin1, but not control GFP, localized to the centrosomes (Fig. 3A). Interestingly, relative to nontransfected cells or cells transfected with GFP alone, the number of cells containing abnormal numbers of centrosomes (more than two per cell) was increased in cells overexpressing Pin1 (Fig. 3B). More impressively, such cells containing an abnormal centrosome number were markedly reduced by the expression of dn-Pin1 (Fig. 3B). These results indicate that inhibition of Pin1 suppresses the centrosome amplification that usually occurs in S-arrested CHO cells.
|
9 to 10 passages. Therefore, we used Pin1+/+ and Pin1/ MEFs at passage numbers lower than four, which displayed similar cell cycle profiles based on flow cytometry analysis (Fig. 3C). In order to monitor centrosome duplication in S-phase cells, MEFs were pulse-chased with BrdU for 3 h, followed by coimmunostaining with antipericentrin and anti-BrdU antibodies to determine the coordination between DNA synthesis and centrosome duplication. Approximately 30% of Pin1+/+ and Pin1/ cells were BrdU-positive (Fig. 3D and E). Importantly, almost all BrdU-positive Pin1+/+ cells contained two centrosomes per cell (Fig. 3D and E), indicating that centrosomes are already duplicated as expected. Under the same conditions, only
30% of BrdU-positive Pin1/ cells, however, contained duplicated centrosomes, with
65% of the cells containing only a single centrosome (Fig. 3D and E). These results indicate that centrosome duplication is defective during S phase in most Pin1/ cells.
To ensure that this defective centrosome duplication in Pin1/ MEFs is due to loss of Pin1 function, we needed to stably reexpress Pin1 in Pin1/ MEFs. For this purpose, Pin1/ MEFs immortalized using the 3T3 protocol as described previously (41, 68) were infected with the pBabe retroviruses expressing Pin1 or control retroviruses, followed by selection with puromycin to generate stable rescued Pin1/ and control Pin1/ MEFs. Expression of Pin1 in rescued Pin1/ MEFs was comparable to Pin1+/+ MEFs, as confirmed by immunoblotting and immunostaining (data not shown). Furthermore, cell cycle profiles of the immortalized control Pin1/ and rescued Pin1/ MEFs were similar (Fig. 4A), although they were slightly different from those of primary MEFs at early passages (Fig. 3C). Importantly, only
40% of vector control Pin1/ MEFs that were BrdU-positive had duplicated their centrosomes (Fig. 4B), resembling early passages of primary Pin1/ MEFs (Fig. 3E). However,
90% rescued Pin1/ MEFs that were BrdU-positive duplicated their centrosomes (Fig. 4B), which was indistinguishable from those in Pin1+/+ MEFs at early passages (Fig. 3E). These results indicate that the defect in centrosome duplication in Pin1/ MEFs is specifically due to loss of Pin1 function.
|
-tubulin to determine centrosome duplication. After the release, both control Pin1/ and rescued Pin1/ MEFs entered the cell cycle (Fig. 4C and D) and S phase with similar kinetics (Fig. 4E), indicating that these cells have similar cell cycle profiles. However, relative to rescued Pin1/ cells, centrosome duplication was significantly delayed for many hours in Pin1/ MEFs, although they were able to eventually duplicate their centrosomes when reaching G2 phase (Fig. 4F). Interestingly, the inhibition of CP110 has also been shown to delay but not completely block centrosome duplication in U2OS cells (10). These results indicate that loss of Pin1 function drastically delays centrosome duplication without affecting DNA synthesis in mouse embryonic fibroblasts. Overexpression of Pin1 drives centrosome duplication. The above results that inhibition or ablation of Pin1 suppresses centrosome duplication and that Pin1 overexpression correlates with centrosome amplification in human breast cancer suggest that Pin1 overexpression might drive centrosome duplication. Centrosome duplication initiates at the G1/S transition in mammalian cells and is completed during S phase. In contrast to CHO cells, where multiple rounds of centrosome duplication are observed under prolonged S-phase arrest (Fig. 3A and B), such extra rounds of centrosome duplication have not been reported in nontransformed NIH 3T3 cells. However, it has been shown that these S-arrested NIH 3T3 cells are permissive for centrosome duplication and have been easy assays for identifying the role of a specific protein in centrosome duplication (23, 33, 75). Therefore, we examined the effects of Pin1 overexpression on centrosome duplication by transfecting NIH 3T3 cells with GFP-Pin1 or control vector and arresting them in G1/S phase by aphidicolin, followed by examining centrosome number as described previously (10, 23, 75). The S arrest was confirmed by flow cytometry (data not shown), indicating that overexpression of Pin1 is not sufficient to overcome the S arrest. Surprisingly, however, more than 60% of GFP-Pin1 transfected cells contained more than two centrosomes (Fig. 5A and B). In contrast, such centrosome amplification was rarely observed in GFP-transfected cells (Fig. 5A and B). These results demonstrate that overexpression of GFP-Pin1 induces centrosome duplication and accumulation in S-arrested NIH 3T3 cells.
|
To rule out the possibility that the GFP tag affects the function of Pin1 in centrosome regulation, we utilized a plasmid encoding Pin1 fused to a C-terminal myc tag (Pin1-myc) and repeated the experiments. Pin1-myc again potently increased cells containing more than two centrosomes per cell in a dose-dependent fashion (Fig. 5C and D). To confirm that Pin1-myc overexpression causes centrosome amplification, we used electron microscopy to visualize centrioles, which are definitive evidence for centrosome amplification, in Pin1-myc overexpression (56). Indeed, these cells contained more than four centrioles per cells. Figure 5E and F show electron microscopic images from one such cell containing at least six centrioles in a single section. These results together indicate that Pin1 overexpression drives multiple rounds of centrosome duplication in S-arrested NIH 3T3 cells.
Pin1-induced centrosome duplication causes abnormal spindle formation, aneuploidy, and cell transformation in NIH 3T3 cells.
It has been shown that Pin1 is widely overexpressed in most human cancers and correlates with poor clinical outcome (3, 5, 67, 82). Given that Pin1 is an important regulator of centrosome duplication and that its overexpression causes centrosome duplication and accumulation (often referred to as centrosome amplification) in S-arrested NIH 3T3 cells, an important question was whether Pin1-induced centrosome amplification has any pathological consequences. Centrosome abnormalities have been shown to cause aberrant spindle formation and chromosome segregation in mitotic phase (7, 18, 33, 56, 70). We therefore first examined whether Pin1 overexpression affects spindle formation and chromosome segregation during mitosis. To address this question, NIH 3T3 cells were stably transfected with either control vector or Pin1-myc and then arrested in S phase by aphidicolin. Twenty-four hours after release from the arrest (about one cell cycle), both spindle formation and cytokinesis were analyzed during the initial mitotic phase (Fig. 6A). Interestingly, most Pin1-expressing cells, but not vector control cells, contained more than two centrosomes (Fig. 6B). Many of these cells with supernumerary centrosomes underwent bipolar divisions, with multiple numbers of centrosomes coalescing at the two broad spindle poles as reported previously (25). However,
20% of these Pin1-expressing cells containing supernumerary centrosomes displayed multipolar spindle formation and nucleation (Fig. 6B and C). These cells subsequently underwent abnormal chromosome segregation and cytokinesis, with one cell being divided into three daughter cells (Fig. 6D). These data indicate that Pin1-induced centrosome amplification leads to chromosome missegregation and abnormal cell division.
|
Centrosome defects and resulting chromosome instability have been suggested to play an important role in oncogenesis (7, 18, 33, 56, 70). Given that Pin1 overexpression results in increased genetic instability and aneuploidy in nontransformed NIH 3T3 cells, we next explored whether these Pin1-overexpressing cells have any transforming phenotypes by subjecting them to focus formation and soft agar colony formation assays. Cells expressing Pin1-myc exhibited a significantly higher number of foci in plastic plates than vector control cells (Fig. 6G). Furthermore, Pin1-myc-expressing cells, but not vector control cells, were capable of forming colonies in soft agar (Fig. 6H). These results demonstrate that Pin1-overexpressing NIH 3T3 cells display various cell transformation properties. Taken together, these results indicate that Pin1 overexpression induces centrosome amplification, chromosome instability, and cell transformation in NIH 3T3 cells.
Overexpression of Pin1 induces centrosome amplification in mouse mammary glands. Given that Pin1 overexpression induces centrosome amplification, chromosome instability, and cell transformation in vitro, a key question is whether it has a similar function in vivo. This question is also critical since nothing is known regarding whether Pin1 overexpression is sufficient to induce cancer development in vivo, even though Pin1 has been shown to overexpress in many human cancers and to be important for several oncogenic pathways. To address this question, we generated transgenic mice expressing human Pin1 cDNA under the transcriptional control of the MMTV long terminal repeat promoter/enhancer (Fig. 7A), an approach widely used to access the tumorigenicity of individual oncogenes in breast cancer in vivo (30, 54, 73). To distinguish exogenous Pin1 from endogenous protein, we tagged Pin1 with an HA tag that does not affect Pin1 function in vivo (67, 82). Transgenic mice were first identified by PCR-based genotyping (Fig. 7A) and then confirmed by immunoblotting and immunostaining analyses using anti-HA and anti-Pin1 antibodies (Fig. 7B and D). Pin1 was overexpressed in many, but not all, mammary epithelial cells in both transgenic lines (Fig. 7B and D), as shown for many other MMTV-driven transgenes (9, 11, 31). Two independent transgenic mouse lines, lines 17 and 23, overexpressed Pin1 at similar levels with similar distribution patterns in mammary epithelial cells (Fig. 7B and D). They were further selected to generate homozygous females, which were bred to produce litters two to three times. The phenotypes below were observed in both MMTV-Pin1 transgenic mouse lines at similar frequencies.
|
2% of MECs had similar centrosome amplification in control mice (Fig. 7D), indicating that centrosomes are amplified in MMTV-Pin1 transgenic mammary glands. However, no detectable increase in the centrosome number was detected in control mice. These results indicate that overexpression of Pin1 in mammary glands causes centrosome amplification.
To more accurately evaluate the frequency of MECs with centrosome amplification relative to aging in transgenic mice, we isolated primary MECs from mouse mammary glands without tumors in MMTV-Pin1 transgenic and control mice at different ages and then cultured them for a few days to a week as described previously (80); this was followed by immunostaining with antipericentrin antibodies. Under these primary culture conditions,
10% of MECs derived from 5-month-old control mice contained more than two centrosomes per cell and this number did not significantly change with aging (Fig. 7E and F). In contrast, the percentage of primary MECs with centrosome amplification significantly increased with aging in MMTV-Pin1 transgenic mice. The frequency of MECs with centrosome amplification in Pin1 transgenic mice that were 4 months old was close to that for controls; however, this frequency was significantly increased to 30% by 6 months of age and then further increased slowly to
45% by 18 to 24 months of age (Fig. 7E and F). Taken together, these immunostaining results on tissue sections and primary cell cultures all indicate that overexpression of Pin1 causes centrosome amplification in mouse mammary glands and the effect appears to be more obvious with aging.
Overexpression of Pin1 induces mammary hyperplasia and malignant mammary tumors with overamplified centrosomes in transgenic mice. To examine whether Pin1 overexpression results in any pathological changes in mammary glands, we first performed whole mount analysis and histological examination of mammary glands for MMTV-Pin1 and control mice at various ages. MMTV-Pin1 mice showed progressive hyperplastic changes in an age-dependent manner. At an age of 6 months, when centrosome amplification was detected (Fig. 7), there were no detectable histological changes in MMTV-Pin1 mice relative to controls (Fig. 8). Mammary epithelial hyperplasia, detected as early as 10 months of age, was multilayered and often appeared to originate from ducts (Fig. 8). By an age of 18 months, numerous hyperplastic lesions were observed in the majority of mammary glands in most of the transgenic mice that were examined. In contrast, such hyperplastic changes were rarely observed in control mice (Fig. 8). These results indicate that Pin1 overexpression induces mammary hyperplasia.
|
|
-tubulin and anti-
-tubulin antibodies. Centrosome amplification was strikingly obvious in these tumor cells (Fig. 9D and E); close to 80% of tumor cells contained more than two centrosomes per cell, whereas only 20% of MECs from 18-month-old control mice had more than two centrosomes per cell (Fig. 9F). Moreover, as is the case in NIH 3T3 cells overexpressing Pin1 (Fig. 6C to D), although many of these tumor cells with supernumerary centrosomes underwent bipolar divisions, cells displaying multipolar spindle formation and nucleation were readily detected, resulting in chromosome missegregation and aneuploidy (Fig. 9E). Taken together, these results indicate that overexpression of Pin1 leads to centrosome amplification, chromosome instability, and oncogenesis both in cell cultures and in transgenic mice. | DISCUSSION |
|---|
|
|
|---|
Protein phosphorylation by Pro-directed kinases such as Cdk2 has been shown to play a key role in regulating centrosome duplication in mammalian cells (14, 27, 56). However, little is known about whether centrosome duplication is further regulated after phosphorylation. Recent studies indicate that Pin1-mediated phosphorylation-specific prolyl isomerization regulates the conformation and function of a subset of proteins at the postphosphorylation level (42, 45, 79). Our current study has uncovered a novel role for Pin1 in regulating centrosome duplication and amplification based on the following observations.
Pin1 localizes to and copurifies with centrosomes during interphase when they are duplicated, but not during mitosis when they are separated, even though proteins at centrosomes are heavily phosphorylated during mitosis (18, 56, 70). This dynamic association might provide an explanation for why Pin1 is not identified in the recent proteomic identification of core centrosome proteins (1). Functionally, Pin1 ablation in mouse embryonic fibroblasts drastically delays centrosome duplication without affecting DNA synthesis, indicating a requirement of endogenous Pin1 for the coordination between centrosome duplication and DNA synthesis. Furthermore, the inhibition of Pin1 function in CHO cells is able to suppress the ability of these cells to undergo multiple rounds of centrosome duplication under S-arrest conditions, suggesting a role for Pin1 in centrosome amplification. Indeed, overexpression of Pin1 in nontransformed NIH 3T3 cells potently drives multiple rounds of centrosome duplication under S-arrest conditions. Importantly, the ability of Pin1 to induce centrosome amplification is completely abolished by point mutations that disrupt the ability of Pin1 to bind to or isomerize pSer/Thr-Pro motifs. Moreover, transgenic overexpression of Pin1 in mouse mammary epithelial cells also potently induces centrosome amplification. Together with the previous findings that Pin1 is significantly elevated at the G1/S transition (66) and is also subjected to phosphorylation during the cell cycle (46), these results suggest that Pin1 function is normally needed for the coordination of centrosome duplication and DNA synthesis and its aberration can lead to centrosome amplification.
Our findings also suggest that Pin1-induced centrosome abnormalities may contribute to chromosome instability and oncogenesis and further support the idea of Pin1 as a new anticancer target (43). Centrosome amplifications are often found in many human cancers such as breast, prostate, colon, and lung cancers, where Pin1 is often overexpressed (3, 5, 12, 26, 38-40, 59, 60, 62, 65, 67, 71, 82). Like Pin1 overexpression (3), centrosome defects have been shown to correlate with poor clinical outcome (12, 61, 71), suggesting a possible functional interaction between Pin1 overexpression and centrosome abnormalities. Indeed, we have found that Pin1 levels are significantly correlated with the degree of centrosome amplification in human breast cancer tissues. Furthermore, the overexpression of Pin1 in nontransformed NIH 3T3 cells induces centrosome amplification and chromosome missegregation, eventually leading to aneuploidy and oncogenic transformation. Moreover, transgenic overexpression of Pin1 in mouse mammary glands potently induces centrosome amplification, eventually leading to mammary hyperplasia and malignant mammary tumors with overamplified centrosomes. Given these marked effects of Pin1 overexpression on centrosome amplification in vitro and in vivo and given the well-documented centrosome defects in human cancers, it is likely that Pin1-induced centrosome amplification promotes and/or contributes to oncogenesis. These results also suggest that inhibition of Pin1 might offer an attractive new option for inhibiting centrosome amplification and chromosome instability in cancer cells.
How Pin1 regulates centrosome duplication and how its deregulation leads to centrosome amplification remain to be defined. Pin1 has been shown to increase cyclin D1 protein stability and its transcription in collaboration with Ras/JNK, Wnt/ß-catenin and NF-
B pathways (41, 65, 67, 82). Since cyclin D1 plays an essential role in breast cancer development (15, 37, 72, 77, 86) and can increase centrosome duplication in vitro (55), it is possible that Pin1 might regulate centrosome duplication and breast cancer through cyclin D1 and its upstream regulators. In addition, our preliminary results showed that Pin1 binds to several important proteins that are located at centrosomes and phosphorylated Cdk2 substrates and that inhibition of Cdk2 function can suppress the ability of Pin1 to induce centrosome amplification (data not shown), suggesting that Pin1 might also regulate centrosome duplication via Cdk2 substrates on centrosomes. Notably, it has been shown that the Pin1 gene is an Rb/E2F downstream target gene (66) and that G1 Cdks and their downstream Rb/E2F pathway play an important role in centrosome duplication during S phase (20, 21, 32, 36, 49, 52). Therefore, it is possible that during the G1/S transition in normal cells, growth signals activate Cdk kinases which turn on the Rb/E2F pathway, thereby increasing Pin1 expression. This increase in Pin1 levels may in turn promote centrosome duplication by controlling the function of the proteins at centrosomes or their upstream regulators that have been phosphorylated by Cdks in a positive feedback mechanism. However, deregulation of this mechanism due to the constitutively active Rb/E2F pathway and Pin1 overexpression might contribute to centrosome amplification in cancer cells. Therefore, it would be interesting to identify all Pin1-binding proteins at the G1/S transition in normal and cancer cells and then to elucidate their function in centrosome duplication and amplification.
In summary, we have shown that Pin1 plays a critical role in regulating centrosome duplication during the cell cycle and its overexpression causes centrosome amplification and chromosome missegregation, which leads to chromosome instability and oncogenesis in vitro and in vivo. These results provide the first evidence for novel postphosphorylation regulation of centrosome duplication during the cell cycle and its significance in centrosome abnormalities and oncogenesis. These results also suggest that Pin1 may be a new anticancer target for inhibiting centrosome defects and chromosome instability, which are common events in cancer cells.
| ACKNOWLEDGMENTS |
|---|
A.R. and J.L. are a Leukemia and Lymphoma Society Special Fellow and a Human Frontier Science Program Fellow, respectively. This study was supported by the NIH grant GM58556 to K.P.L.
| FOOTNOTES |
|---|
These authors contributed equally to this work. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Atchison, F. W., B. Capel, and A. R. Means. 2003. Pin1 regulates the timing of mammalian primordial germ cell proliferation. Development 130:3579-3586.
3. Ayala, G., D. Wang, G. Wulf, A. Frolov, R. Le, T. Wheeler, J. M. Sowadski, K. P. Lu, and L. Bao. 2003. Pin1 is a novel prognostic marker in prostate cancer. Cancer Res. 63:6244-6251.
4. Balczon, R., L. Bao, W. E. Zimmer, K. Brown, R. P. Zinkowski, and B. R. Brinkley. 1995. Dissociation of centrosome replication events from cycles of DNA synthesis and mitotic division in hydroxyurea-arrested Chinese hamster ovary cells. J. Cell Biol. 130:105-115.
5. Bao, L., G. Sauter, J. Sowadski, K. P. Lu, and D. Wang. 2004. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am. J. Pathol. 164:1727-1737.
6. Borel, F., O. D. Lohez, F. B. Lacroix, and R. L. Margolis. 2002. Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc. Natl. Acad. Sci. USA 99:9819-9824.
7. Bornens, M. 2002. Centrosome composition and microtubule anchoring mechanisms. Curr. Opin. Cell Biol. 14:25-34.[CrossRef][Medline]
8. Bornens, M., M. Paintrand, J. Berges, M. C. Marty, and E. Karsenti. 1987. Structural and chemical characterization of isolated centrosomes. Cell Motil. Cytoskeleton 8:238-249.[CrossRef][Medline]
9. Cato, A. C., J. Weinmann, S. Mink, H. Ponta, D. Henderson, and A. Sonnenberg. 1989. The regulation of expression of mouse mammary tumor virus DNA by steroid hormones and growth factors. J. Steroid Biochem. 34:139-143.[CrossRef][Medline]
10. Chen, Z., V. B. Indjeian, M. McManus, L. Wang, and B. D. Dynlacht. 2002. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev. Cell 3:339-350.[CrossRef][Medline]
11. Choi, Y. W., D. Henrard, I. Lee, and S. R. Ross. 1987. The mouse mammary tumor virus long terminal repeat directs expression in epithelial and lymphoid cells of different tissues in transgenic mice. J. Virol. 61:3013-3019.
12. D'Assoro, A. B., S. L. Barrett, C. Folk, V. C. Negron, K. Boeneman, R. Busby, C. Whitehead, F. Stivala, W. L. Lingle, and J. L. Salisbury. 2002. Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res. Treat. 75:25-34.[CrossRef][Medline]
13. D'Assoro, A. B., R. Busby, K. Suino, E. Delva, G. J. Almodovar-Mercado, H. Johnson, C. Folk, D. J. Farrugia, V. Vasile, F. Stivala, and J. L. Salisbury. 2004. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene 23:4068-4075.[CrossRef][Medline]
14. D'Assoro, A. B., W. L. Lingle, and J. L. Salisbury. 2002. Centrosome amplification and the development of cancer. Oncogene 21:6146-6153.[CrossRef][Medline]
15. Deshpande, A., P. Sicinski, and P. W. Hinds. 2005. Cyclins and cdks in development and cancer: a perspective. Oncogene 24:2909-2915.[CrossRef][Medline]
16. Dougherty, M. K., J. Müller, D. A. Ritt, X. Z. Zhou, M. Zhou, T. D. Copeland, T. P. Conrads, T. Veenstra, K. P. Lu, and D. K. Morrison. 2005. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17:215-224.[CrossRef][Medline]
17. Doxsey, S. 2002. Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol. Cell 10:439-440.[CrossRef][Medline]
18. Doxsey, S., D. McCollum, and W. Theurkauf. 2005. Centrosomes in cellular regulation. Annu. Rev. Cell Dev. Biol. 21:411-434.[CrossRef][Medline]
19. Doxsey, S., W. Zimmerman, and K. Mikule. 2005. Centrosome control of the cell cycle. Trends Cell Biol. 15:303-311.[CrossRef][Medline]
20. Duensing, S., A. Duensing, C. P. Crum, and K. Munger. 2001. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res. 61:2356-2360.
21. Duensing, S., L. Y. Lee, A. Duensing, J. Basile, S. Piboonniyom, S. Gonzalez, C. P. Crum, and K. Munger. 2000. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. USA 97:10002-10007.
22. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.[CrossRef][Medline]
23. Fisk, H. A., and M. Winey. 2001. The mouse Mps1p-like kinase regulates centrosome duplication. Cell 106:95-104.[CrossRef][Medline]
24. Fujimori, F., K. Takahashi, C. Uchida, and T. Uchida. 1999. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G0 arrest. Biochem. Biophys. Res. Commun. 265:658-663.[CrossRef][Medline]
25. Fukasawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude. 1996. Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747.[Abstract]
26. Ghadimi, B. M., D. L. Sackett, M. J. Difilippantonio, E. Schrock, T. Neumann, A. Jauho, G. Auer, and T. Ried. 2000. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 27:183-190.[CrossRef][Medline]
27. Goepfert, T. M., Y. E. Adigun, L. Zhong, J. Gay, D. Medina, and W. R. Brinkley. 2002. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res. 62:4115-4122.
28. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.[CrossRef][Medline]
30. Hennighausen, L. 2000. Mouse models for breast cancer. Breast Cancer Res. 2:2-7.[CrossRef][Medline]
31. Hennighausen, L., R. J. Wall, U. Tillmann, M. Li, and P. A. Furth. 1995. Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. J. Cell Biochem. 59:463-472.[CrossRef][Medline]
32. Hinchcliffe, E. H., C. Li, E. A. Thompson, J. L. Maller, and G. Sluder. 1999. Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 283:851-854.
33. Hinchcliffe, E. H., and G. Sluder. 2001. "It takes two to tango": understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev. 15:1167-1181.
34. Katayama, H., K. Sasai, H. Kawai, Z. M. Yuan, J. Bondaruk, F. Suzuki, S. Fujii, R. B. Arlinghaus, B. A. Czerniak, and S. Sen. 2004. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 36:55-62.[CrossRef][Medline]
35. Kuriyama, R., S. Dasgupta, and G. G. Borisy. 1986. Independence of centriole formation and initiation of DNA synthesis in Chinese hamster ovary cells. Cell Motil. Cytoskeleton 6:355-362.[CrossRef][Medline]
36. Lacey, K. R., P. K. Jackson, and T. Stearns. 1999. Cyclin-dependent kinase control of centrosome